Valencia's public health research foundation specializing in vaccine effectiveness, infectious disease epidemiology, biobanking, and population health surveillance across Europe.
FISABIO is the public health research foundation of the Valencia region in Spain, focused on biomedical and health services research. Their core work spans vaccine effectiveness monitoring, infectious disease epidemiology (tuberculosis, influenza, RSV), and population health surveillance including birth defects registries and human biomonitoring. They also contribute to digital health applications, including deep learning for biomedical imaging and remote clinical trial infrastructure. Increasingly, they bridge public health data systems with computational approaches — biobanking, predictive modeling, and exposome research.
Led DRIVE (largest project, €3.9M) on vaccine effectiveness, coordinated VACMA on vaccine media analytics, and participated in VITAL, I-CONSENT, and PROMISE on RSV/influenza surveillance.
Participated in TB-ACCELERATE and TB-RECONNECT on tuberculosis genomics and epidemiology, and PROMISE on RSV disease burden.
Participated in EUROlinkCAT establishing linked cohorts for congenital anomalies, and contributed to SchoolFood4Change on children's health.
Third-party contributor to HBM4EU (European Human Biomonitoring Initiative) and ATHLETE (exposome research), and involved in ConcePTION's biobank work for pregnancy pharmacovigilance.
Participated in DeepHealth applying deep learning to biomedical imaging, Trials@Home for remote clinical trials, and Stance4Health for personalized nutrition technology.
Participated in ConcePTION for pregnancy pharmacovigilance and contributed to ATHLETE studying environmental exposures during pregnancy and childhood.
In their earlier H2020 period (2015–2018), FISABIO focused on disease registries, child health surveillance, and public communication — projects like EUROlinkCAT tracked congenital anomalies using hospital discharge data, while I-CONSENT addressed informed consent guidelines for vulnerable populations. From 2019 onward, a clear shift emerged toward computational and data-intensive public health: biobanking, deep learning for biomedical applications, remote clinical trials, exposome research, and predictive modeling for medication safety. This reflects a broader move from traditional epidemiological registry work toward technology-enhanced population health research.
FISABIO is moving from traditional epidemiological surveillance toward integrating AI, biobank infrastructure, and exposome science into their public health research — making them increasingly relevant for digitally-enabled population health projects.
FISABIO operates primarily as an active partner in large European consortia (12 of 19 projects as participant), but has demonstrated coordination capacity in four projects including DRIVE, their flagship €3.9M vaccine effectiveness study. With 373 unique consortium partners across 39 countries, they are a well-connected hub in European health research rather than a closed-network organization. Their mix of coordinator and third-party roles suggests flexibility — they can lead public health studies where they have domain authority, or contribute specialized data and cohort access to broader initiatives.
FISABIO has collaborated with 373 unique partners across 39 countries, making them one of the more broadly connected health research foundations in Spain. Their network spans most of Europe with strong ties in public health, vaccine research, and epidemiological surveillance communities.
FISABIO combines regional public health authority (access to Valencia's health system data, biobanks, and patient cohorts) with European-scale research collaboration. This dual position — embedded in a real healthcare system while networked across 39 countries — makes them valuable for projects needing both ground-level clinical data and multi-country coordination. Their particular strength in vaccine effectiveness monitoring, built through leading the €3.9M DRIVE project, gives them credibility that few regional research foundations can match.
